Fig. 5From: Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas a In vivo effect of trabectedin (Et-743) and rucaparib combination. The doubling time was calculated from the tumor progression curve. b Tissue pictures of four representative tumors, the red arrows show the necrotic areas. c Effect of combination of trabectedin (Et-743) and rucaparib on a PDX model of UPS. d tissue pictures of four representative tumorsBack to article page